AMR Industry Alliance 2020 report launches on 16 January 2020
The AMR Industry Alliance was established in 2017. Representing a diverse coalition of biotechnology, diagnostics, generics, and large research-based biopharmaceutical companies and associations, the Alliance drives progress on AMR by the life sciences industry. Approximately 100 life companies and trade associations from 20 countries, it covers 30% of the volume of sales and close to nearly all novel products. The 2020 edition of the AMR Industry Alliance report to be released on 16 January will provide a unique snapshot of the life sciences industry’s collective efforts and leadership in delivering on their commitments to tackle the rise of antimicrobial resistance on the global level.
Alliance member companies were surveyed and submitted data in 2019 quantifying their efforts on AMR relating to 15 commitments. Based on those commitments the Alliance’s metrics on combating AMR have been developed across four areas: Research & Science, Access, Appropriate Use, and Manufacturing & Environment. The consultancy SustainAbility has compiled the results.
The data and case studies collected and published in the 2020 Alliance report provide insights into the practical steps Alliance’s members are taking to curb the spread of antimicrobial resistance in the areas of research and science, access, appropriate use, as well as steps to reduce the environmental impact of manufacturing. The report outlines a forward-looking agenda listing the next steps which the Alliance is committed to take. Professor Dame Sally Davies, U.K. Special Envoy on Antimicrobial Resistance and co-convener of the UN Interagency Coordination Group (IACG) on AMR, authored the foreword.
Following the launch, the Alliance will host a high-level meeting to discuss the report findings with the AMR global health community in March 2020.
AMR INDUSTRY ALLIANCE MEMBERS
For the full list of members, please follow this link.
|Company Scope||Completion of the survey is a mandatory requirement of Alliance membership, which enables the Alliance to report more comprehensively on its progress and the shared challenges in tackling AMR.|
|Disease Scope||All infectious diseases caused by bacterial pathogens. This includes but is not limited to tuberculosis, pneumonia, gonorrhea, skin/soft tissue infections. Some metrics refer to public health priorities as specific pathogen-drug combinations that are in most need of therapeutic alternatives (e.g. CDC Biggest Threats, WHO Priority Pathogens).|
|Product Scope||Any technology that has the potential to positively impact bacterial infections and/or resistance including but not limited to antibiotics, antifungals, vaccines, alternative technologies (e.g. biologics) and diagnostics.|
|Geographic Scope||Metrics are relevant to the global population where patients in need may reside independently of country GDP/wealth.|
|Survey Scope||A broad product definition has been adopted for R&D to allow for as yet ‘unknown’ solutions to AMR-challenges. Some metrics pertain only to post-launch activities and hence may not be relevant to members without activity in this space.|